Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismNeurotrophin-3 expression stimulants |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanismenkephalinase inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Periphagen Holdings, Inc.
0 Patents (Medical) associated with Periphagen Holdings, Inc.
100 Deals associated with Periphagen Holdings, Inc.
100 Translational Medicine associated with Periphagen Holdings, Inc.